TRVI Stock Forecast & Price Target

Trevi Therapeutics is poised for strong growth in the coming years, with their investigational therapy Haduvio showing consistent and promising results in multiple clinical trials. With a unique combination of central and peripheral mechanisms, Haduvio has the potential to be a first-in-class and best-in-class therapy for chronic cough in multiple indications, including a large unaddressed market in refractory chronic cough. The recent decision by competitor GSK to not progress their therapy in RCC only strengthens Trevi's position in the market, and with strong IP, a robust pipeline, and a solid balance sheet, Trevi is well positioned for success.

Trevi Therapeutics is facing significant challenges in the highly competitive RCC market, as evidenced by the recent discontinuation of GSK's camlipixant. While the company's Haduvio therapy has shown promising results in clinical trials, it may struggle to stand out in a crowded market and attract large pharmaceutical partnerships. Additionally, the company is heavily reliant on the success of Haduvio, leaving it vulnerable to setbacks or failures in clinical trials.